AVROBIO logo
AVROBIO AVRO

Quarterly report 2025-Q3
added 11-06-2025

report update icon

AVROBIO Financial Ratios 2011-2025 | AVRO

Annual Financial Ratios AVROBIO

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

4.6 -0.5 -0.0 -4.4 -7.8 -3.8 - - - - - - -

EPS

0.3 -2.4 -2.8 -3.3 -2.7 -3.6 -8.4 - - - - - -

EV (Enterprise Value)

-35.4 M -9.31 M -155 M 279 M 394 M 59 M 24.2 M 9.98 M - - - - -

EBITDA per Share

0.24 -2.38 -2.74 K -3.27 -2.73 -3.41 - - - - - - -

EV/EBITDA

1.0 -2.2 -5.1 -1.0 - - - - - - -

PEG

- 0.07 -0.29 0.11 - - - - - - -

P/B

0.6 0.7 0.0 2.1 3.0 1.4 - - - - - - -

P/CF

-0.9 -0.6 -0.0 -5.2 -8.2 -4.4 - - - - - - -

ROE %

12.83 -140.49 -70.29 -47.07 -39.23 -37.94 - - - - - - -

ROA %

12.03 -101.87 -58.44 -44.14 -36.39 -34.73 - - - - - - -

ROCE %

10.76 -139.89 -70.12 -47.22 -40.65 -37.63 - - - - - - -

Current Ratio

15.9 3.6 5.9 16.1 14.0 12.3 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios AVROBIO

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.02 -1.07 -0.93 - -1.2 -4.34 -10.97 - -7.62 -8.51 -0.57 - -0.52 -0.64 -0.68 - -0.75 -0.74 -0.65 - -1.01 -0.8 -0.77 - -0.57 -0.67 -0.72 - -0.49 -2.98 -4.51 - -2.85 -1.15 - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - -1.05 - -1.31 -3.82 -9.08 - -7.47 -8.45 -0.57 - -0.52 -0.63 -664 - -739 -731 -0.64 - -1 -0.79 -0.78 - -0.59 -0.67 -0.73 - -0.51 -2.69 -3.34 - -2.8 -1.15 - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-31.22 -35.89 -36.47 -4.11 8.49 32.87 55.43 -19.55 -42.97 -78.99 -117.63 -67.96 -84.81 -78.24 -68.74 -42.60 -57.06 -54.67 -51.80 -36.01 -45.22 -39.98 -37.28 -27.04 -36.53 -36.80 -36.77 -24.83 3.01 40.34 59.89 38.79 38.79 10.95 - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-29.19 -32.82 -32.59 -33.52 -42.61 -41.21 -42.49 -46.98 -64.71 -73.35 -84.72 -53.93 -69.00 -66.33 -60.33 -39.19 -52.75 -51.24 -48.69 -33.76 -42.32 -37.31 -34.68 -25.09 -33.77 -33.90 -33.77 -22.73 -114.46 -197.50 -225.71 -127.81 -127.81 -36.09 - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-35.19 -40.07 -39.06 -6.90 5.78 31.51 53.57 -19.72 -43.15 -79.26 -117.92 -67.45 -84.30 -77.72 -68.45 -42.59 -57.03 -54.61 -51.76 -36.24 -45.95 -41.22 -38.81 -28.16 -38.17 -38.47 -37.35 -24.20 3.34 40.88 59.68 38.52 38.52 10.99 - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

29.2 25.6 22.8 12.6 9.2 7.0 26.3 0.9 14.4 11.3 2.8 3.6 4.1 5.2 5.5 5.9 9.5 13.9 18.9 16.1 16.1 16.1 16.1 13.8 13.8 13.8 13.8 11.8 11.8 11.8 11.8 1.9 1.9 1.9 - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company AVROBIO, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.3 - $ 7.09 M chinaChina
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 5.01 6.26 % $ 831 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.26 0.31 % $ 252 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.06 -6.19 % $ 293 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.27 -3.93 % $ 588 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.88 -1.53 % $ 914 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.31 0.4 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.18 -2.93 % $ 7.65 B australiaAustralia
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.01 1.65 % $ 2.84 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CorMedix CorMedix
CRMD
$ 11.08 -3.57 % $ 564 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 57.6 1.62 % $ 4.86 B schweizSchweiz
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.39 -4.03 % $ 2.05 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 94.09 -0.76 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.23 3.8 % $ 1.27 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 10.87 0.65 % $ 1.41 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.57 0.05 % $ 140 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 16.36 -2.07 % $ 420 M usaUSA
Exelixis Exelixis
EXEL
$ 41.5 1.5 % $ 12 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 4.48 0.82 % $ 246 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 551.02 -2.35 % $ 41.7 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.37 3.04 % $ 14.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.14 1.46 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.88 -1.33 % $ 1.46 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.43 -0.87 % $ 739 M usaUSA
Biogen Biogen
BIIB
$ 173.99 -0.06 % $ 25.3 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.13 -4.38 % $ 110 M usaUSA